HIV infection MedDRA version: 14.1 Level: PT Classification code 10020161 Term: HIV infection System Organ Class: 10021881 - Infections and infestations
Conditions
Interventions
Trade Name: EPIVIR*FL 30CPR RIV 300MG
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: LAMIVUDINE
CAS Number: 134678-17-4
Current Sponsor code: NA
Other descriptive name: NA
Concentration
Sponsors
U.L.S.S. 9 DI TREVISO
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - age: at least 18 years old or older - patient treated with Truvada or Kivexa or Combivir and 3th drugs or Atripla for at least 6 months - Viral load =65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: patients who are at risk of non adherence (alcoholic abuse, intravenous drug users, dementia, language difficulties, homeless).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: To compare the adherence in the two groups receiving the same HAART with different kind of administration (co-formulated versus multiple pills).;Primary end point(s): Evaluation of the adherence difference between baseline and 4-6 months afterwards in the two groups, one switched from co-formulated therapy to more pills, and one continuing co-formulated therapy.;Timepoint(s) of evaluation of this end point: 4-6 months;Main Objective: To compare the adherence in the group switching from co-formulated drugs to multiple pills. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA | — |
Countries
Italy
Contacts
Public ContactNUCLEO DI RICERCA CLINICA
ULSS n. 9 di TREVISO
Outcome results
None listed